Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) Director Faith L. Charles purchased 7,550 shares of the business's stock in a transaction that occurred on Friday, April 26th. The stock was bought at an average price of $3.28 per share, with a total value of $24,764.00. Following the completion of the purchase, the director now owns 78,323 shares of the company's stock, valued at approximately $256,899.44. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Abeona Therapeutics Price Performance
NASDAQ ABEO opened at $3.44 on Tuesday. The business has a fifty day moving average price of $7.23 and a two-hundred day moving average price of $5.62. Abeona Therapeutics Inc has a fifty-two week low of $2.83 and a fifty-two week high of $9.01. The stock has a market capitalization of $94.10 million, a PE ratio of -1.33 and a beta of 1.49.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, sell-side analysts expect that Abeona Therapeutics Inc will post -2.05 earnings per share for the current year.
Wall Street Analyst Weigh In
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits | Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you?
In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants.
Absolutely no strings attached.
Secure Your Spot Now
Several equities research analysts recently issued reports on the company. StockNews.com cut Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday, April 23rd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $36.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, April 23rd.
View Our Latest Report on Abeona Therapeutics
Institutional Investors Weigh In On Abeona Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Simplex Trading LLC increased its holdings in shares of Abeona Therapeutics by 1,889.9% during the third quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company's stock worth $59,000 after buying an additional 13,418 shares in the last quarter. Jump Financial LLC acquired a new stake in Abeona Therapeutics in the fourth quarter valued at $199,000. Worth Venture Partners LLC increased its holdings in Abeona Therapeutics by 76.6% in the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company's stock valued at $1,184,000 after purchasing an additional 121,969 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in Abeona Therapeutics in the third quarter valued at $648,000. Finally, Barclays PLC increased its holdings in Abeona Therapeutics by 100.0% in the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company's stock valued at $1,564,000 after purchasing an additional 185,638 shares during the period. 80.56% of the stock is currently owned by institutional investors.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
